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Overall
Paclitaxel
n=57 (29%)
Sirolimus
n=96 (49%)
Everolimus
n=44 (22%) P-value
R-ISR Presentation
Pattern 0.27
Focal 22% 11(19%) 26(27%) 7(16%)
Diffuse 78% 46(81%) 70(73%) 37(84%)
Time index
procedure to
R-ISR, months 
SD
3420 3521 4220 168 0.28
Time index
procedure to
ﬁrst-ISR, months
 SD
1816 1816 2318 74 0.52
R-ISR Treatment
Stent use 53% 48% 57% 52% 0.54
Outcome
Death 4% 9% 1% 2% 0.05
MI 3% 7% 2% 0% 0.12
TVF 18% 23% 17% 14% 0.58
MACE (Death,
MI, and TVF),
21% 32% 18% 16% 0.06
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Background: Previous studies have suggested that early ST (<30 days) may have
a different physiopathology as compared to late events occurring after this period. Our
objective was to investigate the predictors of ST in a large cohort of patients enrolled
in the prospective, single center DESIRE Registry.
Methods: A total of 4,790 pts (7,530 lesions) undergoing elective for emergency PCI
solely with DES (n¼8,058) as a default strategy were enrolled between May/02-Mar/
13. Clinical follow-up (FU) was performed at 1, 6 and 12 months and yearly up to 10
years (97.3%). ST was deﬁned according to the propositions of the Academic
Research Consortium.
Results: The overall incidence of ST was 2.4% (n¼111), given that 95% of patients
were ST-free up to 10 years FU (Kaplan-Meier estimate). Compared to those
without ST, pts with ST had a trend towards more diabetes (36 vs. 30.5%, p¼0.18)
and target lesion in saphenous vein grafts (SVG) (7.4 vs. 5.6, p¼0.10), and
signiﬁcantly more current smoking (41.2 vs. 30.1%, p¼0.02), clinical presentation
of recent MI (29.9 vs. 15.2%, p<0.001), moderate/severe lesion calciﬁcation (36.1
vs. 26.8%, p<0.001), poor left ventricle ejection fraction (<30%) (18.2 vs. 2%,
p¼0.02), multiple DES implanted (56.6 vs. 46.1%, p¼0.03), and residual stenosis
as assessed by QCA (5.0 vs. 3.7%, p¼0.001). In the multivariate model, inde-
pendent predictors of ST were recent MI (<72 hours) (HR 2.66, 95% CI 1.52-4.66,
p¼0.001), recent MI (3-30 days) (HR 1.89, 95% CI 1.08-3.29, p¼0.03), >1 DES
implanted (HR 1.89, 95% CI 1.28-2.80, p¼0.002), SVG (HR 2.21, 95% CI 1.29-
3.78, p¼0.004), and residual stenosis (HR 1.03 per % unit, 95% CI 1.00-1.05,
p¼0.03). Early ST was found in 12.6% of cases (14/111) and independent
predictors for this event were diabetes (OR 2.45, p¼0.01) and recent MI (<72
hours) (OR 3.65, p<0.001).
Conclusions: Early ST was a rare event and was signiﬁcantly associated with diabetes
and clinical presentation of recent MI (< 72 hours). When considering the overall
incidence of ST (2.4%), signiﬁcant independent predictors were recent MI (< 72
hours and between 3-30 days), multiple DES implanted, SVG and stent
underexpansion.
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Background: Stent thrombosis (ST) has been described as a rare event in current
drug-eluting stent (DES) era; however, its occurrence has been associated with rela-
tively high morbimortality. Our objective was to investigate the impact of second
generation DES on the occurrence of ST in daily clinical practice.
Methods: A total of 4,790 pts (7,530 lesions) undergoing elective for emergency PCI
solely with DES as a default strategy were enrolled between May/02-Mar/13. Clinical
follow-up (FU) was performed at 1, 6 and 12 months and yearly up to 10 years
(97.3%). Overall, a total of 8,058 DES were implanted including 1st generationB148 JACC Vol 62/18/Suppl B j October 27–November 1, 20(Cypher/Taxus) in 69% and 2nd generation (Xience/Promus/Resolute/Endeavor/Bio-
Matrix) in 31%, given that mean FU for pts treated with 1st vs. 2nd generation DES
were 5.32.6 vs. 1.11.0, respectively.
Results: Overall, mean age was 64 years, 31% had diabetes, 23% had previous
MI and 41% presented with acute coronary syndrome. Compared to pts treated
with 1st generation DES, those treated with 2nd generation DES had more dia-
betes (p<0.001), multivessel disease (p<0.001), and multiple DES implanted
(p<0.001), but angiographic success was similar in both groups (>99%). The
occurrence curve for ST (ARC) up to 2 years FU with landmark analysis at 1
year is shown in the Figure.Conclusions: Compared to 1st generation DES, the use of 2nd generation DES was
associated with a non-signiﬁcant trend towards less occurrence of ST up to 2 years
FU, given that there were no very late ST found with 2nd generation DES.
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Background: In the ﬁrst generation drug-eluting stent (DES) era, it had reported that
clinical outcome of paclitaxel-eluting stent (PES) deployment was better than siroli-
mus-eluting stent. But clinical outcome of PCI with second generations DES was not
established. Our aim was to investigate the clinical outcomes of hemodialysis (HD)
patients after PCI with DES.
Methods: In 6298 consecutive cases which underwent PCI with DES between April
2007 and June 2012, 182 consecutive patients (247 lesions) on HD patients were
treated with PES (P group: 93 patients, 117 lesions), everolimus-eluting stent (E
group: 54 patients, 78 lesions) or biolimus-eluting stent (B group: 35 patients, 52
lesions) implantation and were follow up to 8 months. The primary endpoints were
angiographic outcomes and MACE (death, myocardial infarction, CABG, target
lesion revascularization: TLR).
Results: Clinical follow up was obtained on all patients. Angiographic follow up
was obtained in 201 lesions (81.4%). No signiﬁcant difference was detected in the
baseline demographic, angiographic, and lesion characteristics. In eight month
follow-up, the mean values of late lumen loss (P group: 0.50.8mm, E:
0.60.8mm, B: 1.00.6mm; p¼0.01), TLR (P group: 9.3%, E: 15.4%, B: 28.9%;
p<0.01) and MACE (P group: 12.7%, C: 19.2%, B: 28.9%; p¼0.04) in P group
was the lowest in these groups. In multivariate analysis, predictors of TLR were
diabetes mellitus (OR: 2.7, 95%CI: 1.1-7.0, p¼0.025), BES deployment (OR: 3.4,
95%CI: 1.5-7.5, p¼0.0027) and product of serum calcium and phosphorus>38
(OR: 3.6, 95%CI: 1.6-8.9, p¼0.0016).
Conclusions: In PCI with DES for HD patients, second generation DES hasn't
improved clinical outcomes. PES deployment is still usefulness today.13 j TCT Abstracts/POSTER/In-stent Restenosis and Stent Thrombosis
